This study explored dietary restriction of the essential amino acid tryptophan as a potential adjuvant cancer therapy. Using the human serum albumin (HSA) scaffold, the authors engineered a tryptophan-depleted protein (TDP) by substituting the native tryptophan at position 238 with phenylalanine (W238F). The TDP was intended as a dietary protein with substantially reduced tryptophan content to enable quantitative tryptophan restriction via diet.
The engineered TDP construct was expressed in the yeast Pichia pastoris expression system. Following expression, the protein was purified using a combination of hollow fiber membrane ultrafiltration and liquid chromatography. These downstream processing steps were used to obtain a purified TDP preparation suitable for compositional analysis and dietary studies.
Purified TDP samples were analyzed by high performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS) to quantify residual tryptophan. Analysis confirmed that the tryptophan content in the purified TDP was 0.35 μg per gram of protein, indicating effective depletion of tryptophan in the engineered product relative to typical dietary proteins.
To test the feasibility of dietary tryptophan restriction for tumor suppression in vivo, the investigators used a gastric adenocarcinoma xenograft model in mice. Animals received a diet formulated around the purified TDP to impose tryptophan restriction and were compared with control animals fed a complete protein diet. The study assessed tumor growth under these dietary conditions to evaluate anti-tumor efficacy of the TDP-based diet.
The TDP-based tryptophan-restricted diet produced a statistically significant suppression of tumor growth compared with the complete protein control diet (reported P = 0.001). End result reporting indicated a 64% reduction in tumor weight in the TDP diet group relative to the control group. These outcome measures constitute the primary efficacy evidence presented in the source abstract.
Based on the engineered production of a low-tryptophan dietary protein and the observed tumor suppression in the xenograft model, the authors present this work as a proof-of-concept for developing engineered dietary proteins as foods for special medical purposes (FSMPs). They propose that such engineered proteins could form the basis of dietary intervention strategies as adjuvants in cancer therapy by targeting amino acid metabolism.
The source text is an abstract and reports key design elements, major methods, and principal outcomes but does not include full experimental details, complete datasets, or extended methodological parameters. Specifics such as the number of animals, exact diet formulations, dosing schedules, statistical methods beyond the reported P value, and safety/tolerability data were not reported in the provided source excerpt. The authors declare no conflict of interest.
Important terms highlighted in the study include tryptophan-depleted protein, Pichia pastoris, HPLC-MS/MS, human serum albumin (HSA) scaffold, foods for special medical purposes (FSMPs), and adjuvant cancer therapy.
The study demonstrates that an engineered HSA-based protein with substantially reduced tryptophan content can be produced in Pichia pastoris, purified, analytically confirmed to contain minimal tryptophan, and used in a dietary intervention that significantly reduced tumor burden in a mouse gastric adenocarcinoma xenograft model (64% tumor weight reduction, P = 0.001). The authors frame these findings as a conceptual and practical foundation for engineered dietary proteins as FSMPs and for dietary amino acid restriction as a potential adjuvant cancer treatment modality. Further methodological and safety details were not provided in the abstract and would require consultation of the full article for comprehensive evaluation.